% Expired Patents = 28.6

EPO Patents = 18

Forward Citations = 84

Loading Chart...

4 inventors (with patents filed for the assignee):

Christophe Bonny (8 out of 24 patents)

Catherine Deloche (6 out of 8 patents)

Jean-Marc Combette (6 out of 8 patents)

4. Claire Abadie (2 out of 4 patents)

14 patents: Sort by Forward Citations

1. 11779628 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2023-10-10),

2. 11331364 - Use for JNK inhibitor molecules for treatment of various diseases (2022-05-17),

3. 10967038 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases (2021-04-06),

4. 10624948 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2020-04-21),

5. 10596223 - JNK inhibitor molecules for treatment of various diseases (2020-03-24),

6. 10023615 - Efficient transport into white blood cells (2018-07-17),

7. 9624267 - JNK inhibitor molecules (2017-04-18),

8. 9610330 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2017-04-04),

9. 9290538 - Cell-permeable peptide inhibitors of the JNK signal transduction pathway (2016-03-22),

10. 9180159 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases (2015-11-10),

11. 9150618 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases (2015-10-06),

12. 9006185 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2015-04-14),

13. 8981052 - JNK inhibitor molecules (2015-03-17),

14. 8748395 - Cell-permeable peptide inhibitors of the JNK signal transduction pathway (2014-06-10),

Company Overview

Xigen Inflammation Ltd. is a biotechnology company based in Limassol, Cyprus, focused on developing innovative therapeutic solutions for inflammatory diseases. The organization specializes in advanced research and technology aimed at understanding and modulating immune responses. By leveraging cutting-edge methodologies, Xigen aims to address unmet medical needs in the field of inflammation, contributing to improved patient outcomes through targeted treatments and novel drug formulations.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#6 in Limassol

#12 in Cyprus

#42,290 in the World

Limassol, Cyprus

Xigen Inflammation Ltd.

Forward Citations = 84

4 inventors:

Christophe Bonny (8 out of 24 patents)

Catherine Deloche (6 out of 8 patents)

Jean-Marc Combette (6 out of 8 patents)

4. Claire Abadie (2 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xigen Inflammation Ltd.. Retrieved from https://idiyas.com/company/xigen-inflammation

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

18 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]